RLAY — Relay Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-07-16.
Performance
Technicals
Others in Healthcare
Measured signals that fired on RLAY
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-08-18 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-30 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-02 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-19 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-17 | Patel Sanjiv President and CEO | Open-market sale 10b5-1 plan | 48.2K | 20.33 | 979.9K |
| 2026-08-14 | Catinazzo Thomas Chief Financial Officer | Open-market sale 10b5-1 plan | 17.7K | 19.74 | 349.7K |
| 2026-07-28 | Bergstrom Donald A President, R&D | Open-market sale | 2.2K | 18.61 | 41.6K |
| 2026-07-28 | Catinazzo Thomas Chief Financial Officer | Open-market sale | 1.5K | 18.61 | 27.2K |
| 2026-07-28 | Rahmer Peter See remarks | Open-market sale | 748 | 18.61 | 13.9K |
| 2026-07-07 | Patel Sanjiv President and CEO | Open-market sale 10b5-1 plan | 48.2K | 19.58 | 943.7K |
| 2026-07-06 | Catinazzo Thomas Chief Financial Officer | Open-market sale 10b5-1 plan | 17.7K | 18.69 | 331.1K |
| 2026-07-06 | Bergstrom Donald A President, R&D | Open-market sale 10b5-1 plan | 8.7K | 18.71 | 162.0K |
| 2026-06-30 | Rahmer Peter See remarks | Open-market sale 10b5-1 plan | 50.0K | 19.09 | 954.5K |
| 2026-06-30 | Patel Sanjiv President and CEO | Grant or award 10b5-1 plan | 3.1K | 6.95 | 21.2K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 277.7M | 27.9M |
| Commodore Capital LP | 169.2M | 17.0M |
| Casdin Capital, LLC | 143.5M | 14.4M |
| BlackRock, Inc. | 129.1M | 13.0M |
| PERCEPTIVE ADVISORS LLC | 97.0M | 9.8M |
| Bellevue Group AG | 77.6M | 7.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 73.5M | 7.4M |
| STATE STREET CORP | 62.0M | 6.2M |
| Nextech Invest, Ltd. | 55.0M | 5.5M |
| TCG Crossover Management, LLC | 42.5M | 4.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-18 | 2026-08-17 | on EDGAR ↗ |
| 4 | 2026-08-18 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-10 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-07 | — | on EDGAR ↗ |
| 424B5 | 2026-08-06 | — | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Relay Therapeutics, Inc. (RLAY) filed form 4 · 2026-08-18 · SEC EDGAR
- Relay Therapeutics, Inc. (RLAY) filed form 4 · 2026-08-18 · SEC EDGAR
Ask the AI about RLAY
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →